Volume 67, Issue 1, Pages (January 2005)

Slides:



Advertisements
Similar presentations
M. Hatch, J. Cornelius, M. Allison, H. Sidhu, A. Peck, R.W. Freel 
Advertisements

Volume 63, Issue 3, Pages (March 2003)
Contribution of dietary oxalate to urinary oxalate excretion
Mike L. Green, Robert W. Freel, Marguerite Hatch  Kidney International 
Volume 61, Issue 3, Pages (March 2002)
Sodium thiosulfate prevents vascular calcifications in uremic rats
Volume 73, Issue 3, Pages (February 2008)
Volume 77, Issue 5, Pages (March 2010)
Sorbitol transport in rat renal inner medullary interstitial cells
Volume 59, Issue 1, Pages (January 2001)
Volume 67, Issue 2, Pages (February 2005)
Volume 67, Issue 5, Pages (May 2005)
Volume 61, Issue 3, Pages (March 2002)
Volume 55, Issue 2, Pages (February 1999)
Vitamin E attenuates crystal formation in rat kidneys: Roles of renal tubular cell death and crystallization inhibitors  H.-S. Huang, J. Chen, C.-F. Chen,
Volume 55, Issue 1, Pages (January 1999)
Volume 80, Issue 4, Pages (August 2011)
Volume 59, Issue 5, Pages (May 2001)
Volume 53, Issue 6, Pages (June 1998)
Volume 84, Issue 5, Pages (November 2013)
Effect of acidosis on urine supersaturation and stone formation in genetic hypercalciuric stone-forming rats  David A. Bushinsky, Marc D. Grynpas, John.
Calcium oxalate crystal localization and osteopontin immunostaining in genetic hypercalciuric stone-forming rats  Andrew P. Evan, Sharon B. Bledsoe, Susan.
Volume 79, Issue 5, Pages (March 2011)
Volume 65, Issue 5, Pages (May 2004)
Volume 65, Issue 2, Pages (February 2004)
Response to ‘Active renal crystal clearance in rats and humans’
A new era in the treatment of calcium oxalate stones?
Volume 55, Issue 1, Pages (January 1999)
Volume 86, Issue 6, Pages (December 2014)
Volume 26, Issue 8, Pages (August 2018)
Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I  Cristina Martin-Higueras,
Volume 74, Issue 7, Pages (October 2008)
Comparative effects of potassium chloride and bicarbonate on thiazide-induced reduction in urinary calcium excretion  Lynda A. Frassetto, Eileen Nash,
Volume 72, Issue 8, Pages (October 2007)
Volume 54, Issue 5, Pages (November 1998)
Acute oxalate nephropathy due to ethylene glycol ingestion
Aquaporin gene delivery to kidney
Volume 53, Issue 5, Pages (May 1998)
Volume 61, Issue 3, Pages (March 2002)
Drosophila: a fruitful model for calcium oxalate nephrolithiasis?
Volume 69, Issue 3, Pages (February 2006)
Volume 58, Issue 4, Pages (October 2000)
Use of a probioitic to decrease enteric hyperoxaluria
Volume 70, Issue 12, Pages (December 2006)
Fractional clearance of high molecular weight proteins in conscious rats using a continuous infusion method  Melissa J. Burne, Tanya M. Osicka, Wayne.
Volume 87, Issue 1, Pages (January 2015)
Volume 72, Issue 1, Pages 8-10 (July 2007)
John H. Wiessner, Linda Y. Hung, Neil S. Mandel  Kidney International 
Volume 59, Issue 2, Pages (February 2001)
Tohru Umekawa, Nasser Chegini, Saeed R. Khan, Ph.D. 
Citrate therapy for polycystic kidney disease in rats
Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1  F. Illies, K.-E. Bonzel, A.-M. Wingen, K. Latta,
Volume 53, Issue 4, Pages (April 1998)
Lu-Cheng Cao, Thomas Honeyman, Julie Jonassen, Cheryl Scheid 
Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita  Kidney International 
Volume 55, Issue 3, Pages (March 1999)
Volume 70, Issue 11, Pages (December 2006)
Association of urinary pH with body weight in nephrolithiasis
The course of the remnant kidney model in mice
Calcium phosphate supersaturation regulates stone formation in genetic hypercalciuric stone-forming rats  David A. Bushinsky, M.D., Walter R. Parker,
Volume 62, Issue 2, Pages (August 2002)
Contribution of dietary oxalate to urinary oxalate excretion
Treatment of the primary hyperoxalurias: A new chapter
Volume 59, Issue 6, Pages (June 2001)
Volume 62, Issue 5, (November 2002)
Effects of FK506 in rat and human resistance arteries
Volume 63, Issue 3, Pages (March 2003)
Volume 56, Issue 5, Pages (November 1999)
Hydroxyproline ingestion and urinary oxalate and glycolate excretion
Volume 55, Issue 1, Pages (January 1999)
Presentation transcript:

Volume 67, Issue 1, Pages 53-60 (January 2005) Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: A potential therapy for primary hyperoxaluria  Sergei V. Chetyrkin, Daniel Kim, John M. Belmont, J.O.N. I. Scheinman, Billy G. Hudson, Paul A. Voziyan  Kidney International  Volume 67, Issue 1, Pages 53-60 (January 2005) DOI: 10.1111/j.1523-1755.2005.00054.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Glyoxylate pathway of oxalate biosynthesis in liver42. 1 is aldehyde dehydrogenase; 2 is glycolate oxidase; 3 is lactate dehydrogenase; and 4 is glyoxylate reductase/hydroxypyruvate reductase. Kidney International 2005 67, 53-60DOI: (10.1111/j.1523-1755.2005.00054.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Effect of pyridoxamine (PM) treatment on urinary oxalate excretion in animals with experimental hyperoxalura. Sprague-Dawley male rats (49 to 52 days old) were randomized on day 1 to receive either ethylene glycol (0.75% vol/vol in drinking water (450mg/day/kg body weight) (ethylene glycol group) or no treatment (control group). After day 14, animals within each group [control (•) or ethylene glycol (▪)] were pair-matched according to their oxalate level. One member of each pair was then randomly assigned to receive pyridoxamine (3mg/mL or 180mg/day/kg body weight) either in drinking water [pyridoxamine (▵)] or in 0.75% ethylene glycol [ethylene glycol + pyridoxamine (♦)]. Urine samples were collected under toluene (to inhibit bacteria growth) in 50mL tubes with hydrochloric acid to minimize spontaneous breakdown of urinary ascorbic acid to oxalate. Urinary oxalate was measured as described in the Methods section. Each symbol represents mean value ± SE (N = 5); at the time points indicated by asterisks, differences between ethylene glycol group and ethylene glycol + pyridoxamine group were statistically significant (P < 0.05). (A) Pyridoxamine was given continuously starting from day 14. (B) In a separate experiment, pyridoxamine treatment started on day 14 and was discontinued on day 28. In this experiment, the elevated levels of oxalate excretion in control group on day 3 are most likely related to animal adaptation. Note that the oxalate levels went down and leveled off before the beginning of pyridoxamine treatment. Kidney International 2005 67, 53-60DOI: (10.1111/j.1523-1755.2005.00054.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 Effect of pyridoxamine (PM) treatment on urinary calcium, creatinine, glycolate, and oxalate. The timing and dosing of treatment were as in Figure 2b, except ethylene glycol (EG) was 0.8% vol/vol in drinking water and pyridoxamine treatment continued until the end of the experiment. Urinary calcium, creatinine, glycolate and oxalate were determined in 24-hour urine samples collected on day 28 of pyridoxamine treatment as described in the Methods section. Each bar represents mean value ± SE; asterisks indicate a significant difference between ethylene glycol group and ethylene glycol + pyridoxamine group (P < 0.05). Control group, N = 3; ethylene glycol group, N = 9; ethylene glycol + pyridoxamine group, N = 8. Kidney International 2005 67, 53-60DOI: (10.1111/j.1523-1755.2005.00054.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 4 Formation of calcium oxalate crystals in rat kidney. Animals from the experiment described in Figure 3 were euthanazed on day 28 of pyridoxamine (PM) treatment and kidneys removed. The crystals were analyzed in the hematoxylin-eosin–stained paraffin kidney sections under polarized light as described in the Methods section. The representative slides for each treatment group are shown; for the ethylene glycol (EG) group, the papillary and the medullary areas of the kidney are presented on separate slides. The statistical analysis of all experimental data is presented in the Table 1. Kidney International 2005 67, 53-60DOI: (10.1111/j.1523-1755.2005.00054.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 5 Correlation between urinary oxalate excretion and papillary crystal deposition. Symbols represent values from individual animals in the same experiment as in Figures 3 and 4. EG is ethylene glycol; EG + PM is ethylene glycol + pyridoxamine. Kidney International 2005 67, 53-60DOI: (10.1111/j.1523-1755.2005.00054.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 6 Trapping of glyoxylate by pyridoxamine. Glyoxylate (10mmol/L) was incubated either alone (▪) or with 15mmol/L pyridoxamine (•). The carbonyl groups of glyoxylate were determined using 2,4-dinitrophenylhydrazine (DNPH) as described in the Methods section. Kidney International 2005 67, 53-60DOI: (10.1111/j.1523-1755.2005.00054.x) Copyright © 2005 International Society of Nephrology Terms and Conditions